Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 7/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.45 |
| ▸ | ALPL | P05186 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | RPA1 | P27694 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6111559 | 0.89 | HCAR3 (0.43) | HCAR3HCAR2ALPLCA12RPA1 | |
| SCHEMBL16763221 | 0.88 | HCAR3 (0.50) | HCAR3HCAR2ALPLCA12RPA1 | |
| SCHEMBL6110252 | 0.86 | HCAR3 (0.47) | HCAR3HCAR2ALPLCA12RPA1 | |
| SCHEMBL6110959 | 0.85 | ALPL (0.46) | HCAR3HCAR2ALPLCA12RPA1 | |
| SCHEMBL1092 | 0.81 | HCAR3 (0.54) | HCAR3HCAR2ALPLCA12TP53 | |
| SCHEMBL9700649 | 0.81 | ALPL (0.46) | HCAR3HCAR2ALPLCA12RPA1 | |
| SCHEMBL6110281 | 0.81 | HCAR3 (0.42) | HCAR3HCAR2ALPLCA12RPA1 | |
| Hydrochloric Acid SCHEMBL31467460 | 0.80 | HCAR3 (0.53) | HCAR3HCAR2ALPLCA12TP53 | |
| SCHEMBL6109364 | 0.80 | HCAR3 (0.44) | HCAR3HCAR2ALPLCA12RPA1 | |
| SCHEMBL1527555 | 0.79 | HCAR2 (0.53) | HCAR3HCAR2ALPLCA12TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ARENA PHARMACEUTICALS INC. (US) | 2006-07-27 | — | — | US | disclosed |
| CN-1720046-A | 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related diseases such as dyslipidemia | ARENA PHARM INC (US) | 2006-01-11 | — | — | CN | disclosed |
| EP-1551403-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032928-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | ARENA PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ACE, ACE2, AGTR2 | HCAR3 82/4885HCAR2 30/4885ALPL 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.